MENLO PARK, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third fiscal quarter and the nine months ended June 30, 2017, and reported on recent corporate developments. Corium’s fiscal year ends on September 30.
